Amgen researchers confirm the lackluster data on the KRAS G12C drug AMG 510 reported at ESMO — but they still have a long way to go exploring options
We learned at ESMO that Amgen’s star cancer drug, the pioneering KRAS G12C player AMG 510, tended toward the unimpressive when applied outside non-small cell lung cancer. And the research team has another batch of data to back that up for ASCO.
In their CodeBreak100 study, investigators reported on 25 patients with advanced tumors outside of both NSCLC and colorectal cancer. Among those, they tracked 22 patients for 7 weeks or longer and found 3 confirmed partial responses (1 appendiceal, 1 melanoma and 1 endometrial tumor). Thirteen had stable disease and the rest progressed.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.